Business Wire

LEO Pharma announces more than half of patients on Kyntheum® (brodalumab) maintain consistent levels of complete skin clearance for more than two years

Jaa

NOT FOR DISTRIBUTION IN THE UNITED STATES

LEO Pharma today announced new Phase III data broadening the evidence base for the efficacy, safety and quality of life benefits of Kyntheum ® (brodalumab), a biologic treatment for people with moderate-to-severe plaque psoriasis. Results from a long-term extension study found Kyntheum® provided sustained high levels of skin clearance (PASII 100) over more than two years in those with moderate-to-severe disease.1 Separate pooled analyses from the AMAGINE clinical trials showed that patients receiving Kyntheum® reported significant health-related quality of life improvements versus placebo.2,3 These data were presented at the 26th European Academy of Dermatology (EADV) annual congress in Geneva, Switzerland.

Psoriasis is a serious, lifelong condition impacting emotional, psychological and physical health. Although its systemic nature often remains unrecognised, people living with psoriasis are at an increased risk of developing serious associated conditions, which further impact quality of life.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.5 For these reasons, lasting skin clearance of symptoms and plaques is an important treatment goal, especially for those with the most severe forms of the disease.5

Results from the AMAGINE-2 extension study confirmed Kyntheum® was able to deliver completely clear skin (PASI 100) in more than half of patients (56.2%, n=779) and almost clear skin (PASI 90) in more than three-quarters of patients (76.8%, n= 779) after two years (120 weeks) of treatment.1 The proportions of patients achieving high levels of skin clearance were comparable to results at year one (week 52) (with 53% and 78% of patients achieving PASI 100 and PASI 90, in year one respectively).1 At week 120, Kyntheum® continued to be well-tolerated with a comparable safety profile, as observed in the 52-week study.1 The most common adverse events were nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infection, arthralgia (joint pain), and headache.1

“These new data are encouraging as they demonstrate the potential long-term efficacy and safety of Kyntheum ® and reinforce its ability to provide psoriasis patients with high levels of lasting skin clearance. It is important that people with moderate-to-severe plaque psoriasis have treatment options that help them to not only achieve clear, healthy skin, but also the capability to relieve the substantial burden the disease places on patients’ everyday lives,” commented Professor Dr. Ulrich Mrowietz, Psoriasis Centre, University Medical Centre, Schleswig-Holstein, Germany.

The burden of psoriasis on quality of life is comparable to other chronic conditions like diabetes and heart diseases.6 Measuring improvements in health-related quality of life is important as they reflect a patient’s experience or perception of disease impact, which is not evaluated by PASI scores alone.7

New pooled analyses of the Phase III AMAGINE(-1,-2,-3) studies showed that significantly greater improvements in health-related quality of life were experienced with Kyntheum® compared with placebo, as measured by the Dermatology Life Quality Index (DLQI)II questionnaire.2,3 At week 12, 59% of Kyntheum® patients reported psoriasis had no impact on their overall quality of life compared to 6% of patients on placebo.3 This was experienced specifically with significant improvements across daily/leisure activities, as well as work/school lives.2 Furthermore, at week 12, 43% of Kyntheum® patients were no longer embarrassed or self-conscious about their psoriasis.3

“Psoriasis is not just a skin condition and the full impact of the disease is often underestimated,” said Gitte Pugholm Aabo, President and CEO, LEO Pharma. “At LEO Pharma we are dedicated to supporting patients with innovative treatment solutions such as Kyntheum ® that can help patients live a more positive life, clear of their skin condition.”

Kyntheum® was granted marketing authorisation by the European Commission in July 20178 and is the first and only biologic that selectively targets the IL-17 receptor subunit A.9,10 By binding to this specific receptor on the cells of the skin, rather than targeting free inflammatory mediators, Kyntheum® blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are involved in psoriasis plaque formation.10,11,12 This mechanism of action is different to all other psoriasis biologics currently available.10,13

A total of 16 Kyntheum® abstracts are being presented at the 2017 EADV annual congress.

- ENDS-

NOTES TO EDITORS

About Kyntheum ®

Kyntheum® (brodalumab) is the only fully human monoclonal antibody that selectively targets the IL-17 receptor subunit A.10,13 By binding to the receptor with high affinity, Kyntheum® effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis.ý13,14

The psoriasis clinical studies programme for Kyntheum® consisted of three clinical trials; AMAGINE-1 (n=661), AMAGINE-2 (n=1831) and AMAGINE-3 (n=1881).15,16 Results showed Kyntheum® 210mg offered more patients complete skin clearance (PASI 100) at 12 weeks compared to patients treated with ustekinumab [AMAGINE-2: 44% (n=272) versus 22% (n=65), p<0.001; AMAGINE-3: 37% (n=229) versus 19% (n=58), p<0.001].15

In AMAGINE-1 83% of patients on Kyntheum® 210mg achieved PASI 75 compared to 3% of patients treated with placebo at 12 weeks [83.3% (n=185) versus 2.7% (n=6), p<0.001] and 76% of patients achieved sPGAIII success versus 1% of patients treated with placebo [75.7% (n=168) versus 1.4% (n=3), p<0.001].16

In the AMAGINE trials more than half (53-56%) of patients on continuous Kyntheum® treatment achieved PASI 100 at week 52.16,17

Patients also reported experiencing improved health-related quality of life after four weeks of treatment with Kyntheum®.18 After 12 weeks of treatment, seven in 10 patients (72%, n=29/40, p<0.0001) reported psoriasis no longer impaired their health-related quality of life, (0/1 DLQI) compared with placebo (5%, n=2/37).18

Data from the three large randomised, controlled AMAGINE clinical trials, found Kyntheum® to be well tolerated, with an acceptable safety profile.19 The most common adverse events were arthralgia (joint pain), headache, fatigue, diarrhoea and oropharyngeal (mouth and throat) pain.16

In July 2016, LEO Pharma entered into a partnership agreement with AstraZeneca granting LEO Pharma exclusive licence to develop and commercialise Kyntheum® in Europe.IV Outside of Europe, Valeant Pharmaceuticals has global commercial rights for brodalumab except in Japan and certain other Asian countries, where the rights are held by Kyowa Hakko Kirin Co. Ltd.

About psoriasis

Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.5 The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).5

An estimated 125 million people worldwide live with psoriasis,20 including nearly 14 million Europeans.21

Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.22 People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,4 including heart disease23,24,25 and metabolic diseases (a combination of diabetes, high blood pressure and obesity).26 Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.27

According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.5

About LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. LEO Pharma offers a comprehensive range of integrated care solutions for control and relief of psoriasis. By expanding its portfolio into biologics, through the approval of Kyntheum®, the company is set to become the world’s leading dermatology company.

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

For more information, visit www.leo-pharma.com

Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal

Follow us on Twitter: www.twitter.com/leohealthyskin

Visit us at LinkedIn: www.linkedin.com/company/leo-pharma

I The Psoriasis Area and Severity Index (PASI) score is used in clinical trials to indicate a % change in disease, i.e. PASI 75 is defined as the proportion of patients that reach ≥ 75% improvement in Psoriasis Area and Severity Index score. PASI 90 or PASI 100 indicates patients who have achieved almost clear or complete skin clearance

II The Dermatology Life Quality Index (DLQI), is a tool commonly used by Dermatologists to assess the quality of life impact of skin disease across areas such as work and social activities as well as symptoms and patients’ feelings about their condition. The data presented at EADV refers to responses to specific sections of this overall DLQI questionnaire.

III sPGA success is defined as patients who achieved a static Physician’s Global Assessment 0 or 1

IV Kyntheum® is not approved by Swissmedic for marketing in Switzerland.

References

1. Lebwohl M, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1790

2. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1791

3. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1792

4. Reich K. Eur Acad Dermatol Venereol. 2012; 26(2):3-11

5. World Health Organization (WHO). Global Report on Psoriasis. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (Accessed September 2017)

6. Rapp SR, et al. J Am Acad Dermatol 1999;41:401-407

7. Grob JJ. J Invest Dermatol. 2007;127:2299-2301

8. European Medicines Agency, European public assessment report, Kyntheum® (brodalumab). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003959/human_med_002054.jsp&mid=WC0b01ac058001d124 (Accessed September 2017)

9. Kyntheum®. Summary of Product Characteristics. 2017

10. Campa M, et al. Dermatol Ther. 2016;6:1–12

11. Beringer A, et al. Trends Mol Med. 2016; 22: 230-41

12. Russell CB, et al. J Immunol. 2014; 192: 3828-36

13. Coimbra S, et al. Core Evidence. 2014;9:89-97

14. Papp K, et al. N Engl J Med 2012;336:1181-9

15. Lebwohl M, et al. N Engl J Med. 2015;373:1318-28

16. Papp K, et al. Br J Dermatol. 2016;175:273–286

17. Supplement to: Lebwohl M, et al. N Engl J Med. 2015;373:1318-28

18. Gordon KB, et al. Br J Dermatol. 2014;170:705–15

19. Attia A, et al. Clin Drug Investig. 2017; DOI: 10.1007/s40261-017-0500-9

20. The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/ (Accessed September 2017)

21. Ortonne J, et al. Eur J Dermatol. 2004;14:41–45

22. National Institute for Health and Care Excellence (NICE) Psoriasis: assessment and management guidelines. Available at: https://www.nice.org.uk/guidance/cg153/chapter/1-Guidance#systemic-therapy (Accessed September 2017)

23. Gelfand JM, et al. JAMA. 2016;296:1735-41

24. Ahlehoff O, et al. Eur Heart J. 2012;33:2054-64

25. Lowes MA, et al. Ann Rev Immunol. 2014;32:227-35

26. Langan SM, et al. J Invest Dermatol. 2012 Mar; 132(3 0 1): 556–562

27. Dalgard F, et al. JID. 2015;135(4), 984-991

Contact information

LEO Pharma
Global media contacts
Henrik Steen Heskjær Kyndlev
Head of Global External Communication
Email: HDTDK@leo-pharma.com
Mobile: +45 3140 6180
or
Marie Schleimann Nordlund
Snr Global Patient Communication Manager
Email: marie.nordlund@leo-pharma.com
Mobile: +45 3126 3734

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

First Westinghouse AP1000® Nuclear Plant Sanmen 1 Completes Initial Criticality21.6.2018 23:24Tiedote

Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) announced today that the world’s first AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China has successfully completed initial criticality. “Today we completed the final major milestone before commercial operation for Westinghouse’s AP1000 nuclear power plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “We are one step closer to delivering the world’s first AP1000 plant to our customer and the world – with our customers, we will provide our customers in China with safe, reliable and clean energy from Sanmen 1.” Following initial criticality will be connection to the electrical grid. Once plant operations begin at Sanmen 1, it will be the first AP1000 nuclear power plant in operation, offering innovative passive safety system technology, multiple layers of defense and advanced controls for unequaled reliability and safety. Commentin

Westinghouse Loads Fuel in Second AP1000® Nuclear Power Plant21.6.2018 23:07Tiedote

Westinghouse Electric Company and its customers, China State Nuclear Power Technology Corporation (SNPTC) and Shangdong Nuclear Power Company Limited (SDNPC) announced today that Haiyang Unit 1, the AP1000 nuclear power plant located in Haiyang, Shandong Province, China, has begun to load fuel. “This is a great day for Westinghouse, our China partners and the nuclear industry. Haiyang Unit 1 continues to demonstrate our ability to deliver safe, innovative solutions for power generation,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. He added, “Westinghouse will continue to deploy AP1000 technology throughout the world and demonstrate our technical leadership in the nuclear energy industry.” Fuel load at Haiyang Unit 1 commenced at 7:36 p.m. (GMT+8) today. Earlier this summer, in preparation for fuel load, Haiyang Unit 1 successfully completed the necessary testing and regulatory reviews conducted by China’s National Nuclear Safety Administration (NNS

Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 21:23Tiedote

Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo

Philip Morris International Makes Call to Creative, Media and Communications Communities21.6.2018 21:13Tiedote

Philip Morris International Inc. (“PMI”) (NYSE: PM), today announced a bold call to action for the creative, media and communications communities to embrace its ongoing commitment to creating a smoke-free world. As part of this initiative, PMI will offer smoke-free alternatives wherever we can, including heated tobacco products and e-cigarettes, to current smokers in the industry who would otherwise continue to smoke. During a keynote at the PMI Science Lounge at The Cannes Festival of Creativity, SVP of Communications Marian Salzman said, “We are asking the creative community to join us in raising awareness of the potential of science, technology and innovation for those who smoke and the people around them.” The move is part of PMI’s vision to lead the charge towards greater innovation and technology in the tobacco industry, all of which is backed by science. Agencies interested in joining the movement can contact Marian Salzman at marian.salzman@pmi.com. “People who smoke deserve in

IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats21.6.2018 19:30Tiedote

IBC2018, the world’s most influential media, entertainment and technology show, today announces a Cyber Security Forum to expand its position as the preeminent cyber security destination for broadcasters and media. The event will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018, which last year attracted more than 57,000 attendees from 170 countries. The Cyber Security Forum is one-day, invitation-only event that will convene Chief Technology Officers, Chief Information Officers, Chief Information Security Officers and Chief Digital Officers within media and broadcasting for a conversation on the challenges and opportunities presented by cyber security for broadcasters. Attendees will discuss how to anticipate the next cyber threat, how to manage a breach and how to prepare for the future of cyber security. The Cyber Security Forum sits alongside the Telco & Media Innovation Forum and Leaders’ Forum as part of IBC’s Exec

Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe21.6.2018 19:23Tiedote

Mensia Technologies, french MedTech start up, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour. Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in Rennes are computing real time signaling softwares. The neurofeedback technique is non invasive, at home and without drugs. MENSIA KOALA treats ADHD, Attention Deficit Disorders with or without Hyperactivity, children and adolescents. This unique medical device is a therapeutic video game on an interactive tablet connected to the brain activity. Children learn to control their attention by exercising 3 times a week during 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme